CONCORDBIOConcord Biotech Limited
Pharma · Biotechnology · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Debt/Equity: 0.00
- • Promoter holding: 72.5%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • Trend strength (ADX): 28
- • 3-month vs NIFTY: +8.7% relative
- • Bullish Engulfing signal (setup quality 77%)
- • RSI Oversold Reversal signal (setup quality 60%)
Bull case
- • Debt/Equity: 0.00
- • Promoter holding: 72.5%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
Bear case
- • Revenue growth: -24.1% YoY
- • Profit growth: -37.0% YoY
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Revenue growth: -24.1% YoY
- • Profit growth: -37.0% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹52.37). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.